CPIX
CumberlandCDocument history
Earnings documents stored for CPIX.
Investor releaseQuarter not tagged2026-06-26Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
PR Newswire
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Orlando, Florida. The presentation highlighted key updates to the primary findings in the FIGHT DMD trial, reinforcing ifetroban's potential to address the leading cause of death in patients with DMD. The presentation was delivered by Chet R. Villa, MD, a pediatric cardiologist at Cincinnati Children's Hospital Medical Center and one of the leaders of the muscular dystrophy committee in Advanced Cardiac Therapies Improving Outcomes Network (ACTION) as part of the conference program. "Cardiomyopathy is the leading cause of mortality in patients with Duchenne muscular dystrophy, and there are currently no approved treatments that specifically target the underlying cardiac disease," said Dr. Villa. "As a site investigator on the FIGHT DMD trial, I have seen the importance of identifying therapies that protect cardiac function in these young patients. The updated findings being presented today include the reduction in markers of heart muscle injury alongside the previously reported improvement in left ventricular ejection fraction. These demonstrate that ifetroban slows ongoing heart damage in patients with DMD compared to natural history studies, addressing a critical unmet need, and sharing these results with the PPMD community is particularly meaningful." The complete set of slides presented at the PPMD conference is now available on Cumberland's website. The 12-month Phase 2 FIGHT DMD trial (NCT03340675) previously demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group composed of placebo-treated patients combined with propensity score-matched natural history patients. The study findings also included reductions in cardiac damage markers (NT-proBNP and cardiac troponin I) in the high-dose group. All patients who completed th...
Investor releaseQuarter not tagged2026-06-02Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study
MT Newswires
Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study
Cumberland Pharmaceuticals (CPIX) and Vanderbilt Health reported positive phase 2a results for ifetr
Investor releaseQuarter not tagged2026-05-06Cumberland Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat
Cumberland Pharmaceuticals Q1 Earnings Call Highlights
Apotex transaction: Cumberland agreed to sell its U.S. portfolio to Apotex for $100 million in cash (plus about $9 million for inventory, transitional fees and a potential sales milestone) subject to shareholder approval, and plans to pivot to a development-focused company after closing. Q1 financials: Revenue was $9.1 million with a net loss of about $3.3 million (adjusted loss $1.9 million, $0.13 per share); the company generated positive operating cash flow of $387,000 and held $11 million in cash as of March 31, 2026, and said it is no longer targeting double-digit revenue growth for the year given the pending deal. Pipeline progress: Ifetroban received FDA Fast Track designation for Duchenne muscular dystrophy (in addition to prior Orphan and Rare Pediatric designations), and multiple Phase II programs (scleroderma, idiopathic pulmonary fibrosis) are advancing with enrollment and interim safety data reported. Interested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better. Cumberland Pharmaceuticals (NASDAQ:CPIX) executives highlighted a planned strategic transaction with Apotex, updates across several marketed brands, and progress in the company’s late-stage pipeline during the company’s first-quarter 2026 earnings call. Chief Executive Officer A.J. Kazimi said Cumberland has entered into an agreement with Apotex, which he described as “the largest Canadian-based pharmaceutical company,” to integrate the companies’ branded U.S. commercial businesses. Under the terms described on the call, Apotex will acquire Cumberland’s portfolio of marketed products for $100 million in cash, subject to shareholder approval. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Kazimi said Cumberland also expects to receive $9 million in payments for inventory, fees for transitional support services, and an additional milestone payment tied to future product sales. He characterized the agreement as “a significant event” that the company expects will “unlock substantial near-term value” for shareholders and potentially expand patient access to its brands through Apotex’s larger market presence. Both Kazimi and CFO John M. Hamm pointed to the transaction’s expected tax impact. Kazimi said the company estimates resulting income taxes will be “modest,” which he said would allow the net consideration to significantly strengthen Cumberland’s...
Investor releaseQuarter not tagged2026-05-06Cumberland: Q1 Earnings Snapshot
Associated Press
Cumberland: Q1 Earnings Snapshot
NASHVILLE, Tenn. (AP) — NASHVILLE, Tenn. (AP) — Cumberland Pharmaceuticals Inc. (CPIX) on Tuesday reported a loss of $3.3 million in its first quarter. On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 22 cents. Losses, adjusted for non-recurring costs and stock option expense, came to 13 cents per share. The pharmaceutical company posted revenue of $9.1 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CPIX at https://www.zacks.com/ap/CPIX
Investor releaseQuarter not tagged2026-05-06CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
PR Newswire
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders' equity. "We entered 2026 with strong momentum following an outstanding 2025, which featured double-digit revenue growth, the addition of a new product to our portfolio, new international approvals and breakthrough clinical study results," said A.J. Kazimi, Cumberland Pharmaceuticals CEO. "We have built on that momentum through our recently announced Strategic Transaction, which represents an important next step in our Company's evolution, enabling us to sharpen our focus on developing high-value product candidates, while unlocking significant value for our shareholders." RECENT COMPANY DEVELOPMENTS INCLUDE: Strategic Transaction Cumberland recently announced a Strategic Transaction with Apotex Inc., the largest Canadian-based pharmaceutical company, to integrate the branded U.S. commercial businesses. Under the terms of the agreement, Apotex will acquire Cumberland's portfolio of FDA-approved brands for $100 million in cash consideration, subject to Cumberland shareholders' approval and certain other customary closing conditions. This transaction is designed to unlock value and sharpen Cumberland's focus on advancing its pipeline of differentiated product candidates designed to address unmet medical needs. The integration of Cumberland's products will create more critical mass to support patient care and expand product distribution. Following the closing of the transaction, Cumberland will retain its development programs, as well as its majority ownership in Cumberland Emerging Technologies. This positions Cumberland to operate with the profile of an innovative, development-stage biopharmaceutical organization devoted to new medicines for the future. Development Pipeline In addition to its portfolio of FDA-approved brands involved in the transaction with Apotex, Cumberland is developing ifetroban, a potent thromboxane anta...
Investor releaseQuarter not tagged2026-05-06Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby
Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Management announced a transformational agreement to sell its entire branded U.S. commercial portfolio to Apotex for $100 million in cash plus inventory and milestone payments, subject to shareholder approval. The strategic shift transitions Cumberland from a commercial-stage entity to an innovation-driven organization focused on advancing its robust pipeline of product candidates. Performance in Q1 2026 was characterized by a 5% revenue increase in the core portfolio, excluding a prior-year one-time milestone, despite traditional first-quarter seasonality. The divestiture is expected to unlock substantial near-term shareholder value while leveraging Apotex's larger market presence to broaden distribution of the legacy brands. Operational momentum continued with the FDA approval of expanded labeling for Caldolor to include postoperative pain management for patients as young as 3 months. The company secured FDA clearance for the Vaprisol manufacturing facility, enabling them to submit for manufacture and, pending approval of that submission, relaunch the brand later in 2026. Management attributes the successful 2025 performance to double-digit sales growth and significant cash flow, which provided the foundation for this strategic pivot. Following the close of the Apotex transaction, Cumberland will no longer target double-digit revenue growth as it shifts focus toward clinical development. Operating expenses are expected to decrease significantly post-closing as Apotex assumes responsibility for sales, marketing, manufacturing, and FDA fees. Clinical spending levels for 2026 are projected to remain stable as the company prioritizes its ifetroban chemical entity across multiple advanced clinical programs. Management expects to announce interim efficacy results for the Fighting Fibrosis trial in idiopathic pulmonary fibrosis later this year. The company is finalizing regulatory pathways for ifetroban in Duchenne muscular dystrophy following a recent FDA Fast Track designation and follow-up meetings. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. The company expects modest income tax impact from the $100 million sale due to a $30 million tax basis in the assets and over $53 million in tax net operating loss carryforwards. A $3 million milestone payment from...
TranscriptFY2026 Q12026-05-05FY2026 Q1 earnings call transcript
Earnings source - 33 paragraphs
FY2026 Q1 earnings call transcript
Good afternoon, and welcome to the Cumberland Pharmaceuticals first quarter 2026 financial report and company update. This call is being recorded at the company's request and will be archived on its website for one year from today's date. I would now like to turn it over to Emily Kent from the Dalton Agency, who handles Cumberland's communications. Emily, please proceed.
Hello, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its first quarter financial results. The release also provided an overall company update, including key developments during the quarter. The release, which includes the related financial tables, can be found on the company's website at cumberlandpharma.com. During today's call, management will share an overview of those financial results and a company update, including recent developments and a discussion of Cumberland's brands, pipelines, and partners. Participating in today's call are A.J. Kazimi, Cumberland's Chief Executive Officer, Todd M. Anthony, Vice President, Organizational Development, and John M. Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Litigation Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties.
There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics, and others that are beyond the company's control. Those issues are described under the caption Risk Factors in Cumberland's annual report on Form 10-K and any subsequent updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations, so information shared on this call should be considered current as of today only. Also, please remember that the company isn't responsible for updating any forward-looking statements, whether as a result of new information or due to future developments. During today's call, there will be references to several of Cumberland's marketed brands.
Full prescribing and safety information for each brand is included on the individual product website, and you can find links to those sites on the corporate site at www.cumberlandpharma.com. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to GAAP measures can be found in the financial tables of the earnings release that I noted was issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point we will be happy to answer them. Management is also prepared to hold a follow-up conversation with shareholders after the call if you prefer. With that introduction, I'll turn the call over to Cumberland's Chief Executive Officer, A.J. Kazimi.
Well, thank you, Emily, and good afternoon, everyone. We appreciate you joining us today. As Emily mentioned, we'll provide a review of our financial results for the first quarter of 2026. We'll discuss key developments during the period, but we'll also share recent updates. Recall that Cumberland enjoyed an outstanding year in 2025 with double-digit growth in sales, significant cash flow from operations, the addition of a new brand to our portfolio, new international product approvals, and breakthrough clinical study results. I believe those were certainly terrific findings, and I'd like to congratulate our team that was responsible for delivering that performance.
We're pleased to report continued momentum in 2026 as we're off to an excellent start with FDA approval for expanded Caldolor labeling, the initiation of our sales promotional efforts in support of Talicia, the first shipment of Vibativ to China, and FDA clearance of the manufacturing facility which will enable the relaunch of Vaprisol. We've also entered into a transformational agreement that positions Cumberland for the next phase of our company's evolution and growth. Today, I'm delighted to discuss that agreement, which we'd enter into with Apotex, the largest Canadian-based pharmaceutical company, to integrate our branded U.S. commercial businesses. Under the terms of the agreement, Apotex will acquire our portfolio of marketed products for cash consideration of $100 million, subject to our shareholders' approval.
Cumberland will also receive $9 million in payments for inventory, fees for transitional support services, and a milestone payment tied to future product sales. This transaction represents a significant event for Cumberland as it unlocks substantial near-term value for our shareholders. Moreover, our hope and our expectation is that even more patients will benefit from the array of our marketed products given Apotex's larger market presence. It's important to note that with the tax bases associated with the assets involved, combined with the tax loss carryforwards, we are estimating the income taxes resulting from the transaction will be modest. As a result, the net consideration will significantly strengthen our balance sheet. Following the close of the transaction, we intend to focus on advancing our robust pipeline of product candidates to address unmet medical needs, which, if successful, can greatly benefit patients and shareholders alike.
That strategic shift will position Cumberland as an innovation-driven organization, developing new medicines for the future. We believe this transaction is very beneficial on several fronts. It unlocks the near-term value of our branded products. It considerably strengthens our balance sheet. It sharpens our strategic focus on developing new products that represent large market opportunities. It enhances our ability to create and deliver additional value for our shareholders. It also creates a branded business platform with more critical mass that Apotex can build upon to broaden the distribution of our brands and deliver them to more patients. We're confident in the direction of the company and in our ability to execute on this new strategy. With that, I'll now turn the call over to Todd M. Anthony, Vice President, Organizational Development. Todd?
Well, thank you, A.J. You know, in February, we hosted our spring national sales meeting in Nashville, and in attendance were the 50 individuals across the country who interact with our medical community in support of our FDA-approved products through our three national sales divisions. Our hospital sales division, which calls on key institutional accounts across the country, our field sales division that covers select office-based physicians, and the Cumberland Oncology Division, which calls on cancer patients. I'd now like to share our first quarter brand updates. Let's start with Caldolor, our intravenous ibuprofen product. In April, we announced approval from the FDA for an expanded indication for Caldolor. The indication now includes the management of post-operative pain. This approval enhances the clinical utility of Caldolor and supports its role in non-opioid and opioid-sparing pain management strategies.
With this update, Caldolor is indicated for use in adult and pediatric patients ages three months and older for the treatment of pain and fever. This expanded labeling further broadens Caldolor's use across perioperative and acute care settings. Additionally, we resubmitted our application to CMS for Caldolor's inclusion under the NOPAIN Act in the first quarter. This program is designed to support the use of non-opioid pain management therapies. Now let's turn to Sancuso, our transdermal patch, FDA-approved for the management of chemotherapy-induced nausea and vomiting. During the first quarter, we announced the launch of the new Sancuso website, which is designed to provide healthcare professionals and patients with enhanced access to educational resources, clinical information, and expert insights related to the prevention of chemotherapy-induced nausea and vomiting. Next, I'd like to share an update for Talicia, an FDA-approved leading treatment for Helicobacter pylori infection.
In February, we announced the launch of our national sales promotion for Talicia under our co-commercialization agreement with Talicia Holdings, Incorporated, which we jointly own. As a reminder, under that agreement, we assumed responsibility for the distribution and sales promotion of the brand in the United States. As part of the launch, we leveraged our existing field sales division with supporting marketing initiatives designed to increase awareness among gastroenterologists and other prescribers. Recall, we have been awaiting FDA clearance of the site where we have successfully transferred the manufacturing of Vaprisol. Today, I am pleased to announce that the FDA has just reinstated their approval status for that facility, which will enable us to submit for manufacture of Vaprisol there. With approval for our submission, we will then arrange for commercial supplies to support the relaunch of the brand, which is expected this year.
That completes my updates for today. I'll turn it over now to our Chief Financial Officer, John M. Hamm, to review our financial results. John?
Thank you, Todd. During the first quarter, our portfolio of FDA-approved brands delivered combined revenue of $9.1 million, which represented a 5% increase after removing the one-time $3 million milestone payment last year associated with the approval of Vibativ in China. Net revenue by product for the first quarter of 2026 included $1 million for Kristalose, $2.9 million for Sancuso, $2.1 million for Vibativ, $1 million for Caldolor, and $1.9 million for Talicia. Turning to our expenditures, total operating expenses for the first quarter were $12.3 million, resulting in a net loss of approximately $3.3 million for the first quarter. When non-cash expenses are added back, the resulting adjusted loss for the first quarter was $1.9 million or $0.13 a share.
We're pleased to see that our most recent acquisitions resulting in additions of Vibativ, Sancuso, and Talicia to our portfolio have provided a significant positive impact on our financial performance. Note that the shipments for individual brands fluctuate from quarter to quarter based on customer buying patterns, which include the timing of international orders. There's also some seasonality to our business, with orders being strongest in the fourth quarter and traditionally lightest in the first quarter. Therefore, we believe our sales performance is best evaluated on an annual basis. Meanwhile, we did continue to achieve our goal of generating positive cash flow from operations, which totaled $387,000 during the first quarter. As a reminder, we participated in the formation of a new company named Talicia Holdings, Inc., which holds the worldwide rights to the Talicia brand and its related product assets.
Cumberland invested $4 million in exchange for a 30% ownership positions in the new company. We are accounting for this holding using the equity method. Turning to our balance sheet as of March 31st, 2026, we had $71 million in total assets, including $11 million in cash and cash equivalents. Liabilities totaled $49.7 million, including $5 million on our credit facility. Total shareholders' equity was $21.6 million at the end of the first quarter. As A.J. Kazimi mentioned, we had signed an agreement to enter into our strategic transaction. In exchange for the assets associated with our portfolio of commercial products, we expect to receive $100 million cash at closing. We will also receive $9 million in payments for our commercial product inventory and a milestone payment.
Cumberland will support the transition of the products for a monthly fee associated with the transition services agreement. I'd like to note that Cumberland continues to hold over $53 million in tax net operating loss carryforwards, primarily resulting from the prior exercise of stock options. The assets involved in our pending strategic transaction have a tax basis of $30 million. We therefore believe that the income taxes resulting from the transaction will be modest. Given the announced strategic transaction, we are no longer targeting a goal of double-digit revenue growth for the year. Our expenses will be significantly decreased after closing as Apotex will assume responsibility for the sales, marketing, medical, manufacturing, and FDA fees associated with the brands.
I would also point out at this time that we do not see any significant change to our current clinical spending levels for 2026 as we continue to advance our line of product candidates, which are in the advanced stages of development. That completes our financial report for the first quarter of 2026. Back to you, A.J.
Thank you, John. Following the close of the strategic transaction, Cumberland will be an innovation-driven, development-focused company. We'll continue to progress our valuable pipeline of new product candidates designed to improve patient care and their quality of life. Our ifetroban new chemical entity, which is a potent and selective thromboxane receptor antagonist, is being evaluated in several advanced clinical programs for patients with a series of unmet medical needs. It's now been dosed in nearly 1,400 subjects and has been found to be safe and well-tolerated in those individuals, resulting in an outstanding safety database. We previously announced positive top-line results from our completed phase II study in patients with Duchenne muscular dystrophy, a rare fatal genetic neuromuscular disease that results in deterioration of the skeletal, lung, and heart muscles. During the first quarter, the FDA granted Fast Track designation for our ifetroban candidate in these DMD patients.
This designation is intended to accelerate the development and review of therapies addressing serious conditions with unmet medical needs. Importantly, it allows for more frequent FDA interaction, rolling data submissions, and earlier guidance throughout the approval process. The program also previously received both Orphan Drug and Rare Pediatric Disease designations from the FDA. An end-of-phase II meeting was held with the FDA last fall, and we had a follow-up meeting during the first quarter of 2026 to discuss both the DMD study results and to determine the regulatory pathway and requirements for approval. We're finalizing our plans for this important program now, and once completed, we'll announce additional results and expected timelines. Meanwhile, we've also been evaluating our ifetroban product candidate in a clinical program in patients with systemic sclerosis or scleroderma.
Enrollment in that study has been completed. We look forward to announcing top-line findings which will be forthcoming. In addition, we have a phase II clinical study, the Fighting Fibrosis trial, in patients with idiopathic pulmonary fibrosis, the most common form of progressive fibrosing interstitial lung disease. Patient enrollment in that study is well underway in centers across the U.S. An interim safety analysis was conducted evaluating the 1st cohort of patients who completed their 12 weeks of treatment. The independent committee concluded there were no new safety signals. Therefore, no changes in the study conduct were needed. Based on those findings, enrollment in the study has continued. We next expect to announce interim efficacy results later this year. Additional pilot patient studies of ifetroban are also underway through several investigator-initiated trials.
In summary, our clinical programs are focused on select patient populations to helping to address unmet medical needs in markets that are very large from a commercial perspective for a company our size. As we look ahead, we'll work to close our strategic transaction, support the transition of our commercial operations, and sharpen our focus on advancing our exciting pipeline of new product candidates. Lastly, I'd just like to extend my sincere thanks and appreciation to all of those at Cumberland for their unwavering dedication towards the patients we aim to serve every day. We're confident in the direction of the company, our future prospects, and in our ability to execute on our strategy. Thank you again for your continued support and interest in Cumberland. With that, we can open the call for any questions. Operator, please proceed.
Thank you, sir. Ladies and gentlemen, that concludes the company's presentation, and we will now open the calls for questions. Our first question comes from Alyssa Nye from IQ Solutions. Your line is now open. Alyssa, you can ask your question.
Operator, are there other questions?
Yes. We'll go on to the next question. One moment, please. Our next question is Brandon Bishop. The line is now open, Brandon.
Operator, there appears to be difficulties with the questions coming through. There is also an echo.
Yes. Let me see one second. If we can hold for a second, please.
Since we're having difficulty hearing the questions, it's very unfortunate. I suppose what we can do is if you would like to follow a conversation, please reach out to the company. We're happy to schedule a call with you and to answer your questions. Meanwhile, just wanna thank everybody for joining us on today's call. We'll look forward to providing another update in the coming months. Operator?
We have someone coming to fix the situation right now if we wanna hold for just one second.
No, that's okay. We will hold any questions. You can reach out to the company. Make sure that we can get those questions answered.
Hi, everyone. I apologize. I have jumped into the queue. If you'd like, I can go over the Q&A instructions again, and I will open the lines for anyone that's gotten into the queue.
That's okay. We will take our questions privately, if you don't mind.
Absolutely. I apologize for the inconvenience. Thank you.
Thank you.
Investor releaseQuarter not tagged2026-04-29CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a. Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/rik67g7q. Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadoteﾮ (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolorﾮ (ibuprofen) injection, for the treatment of pain and fever; Kristaloseﾮ (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancusoﾮ (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisolﾮ (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativﾮ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Taliciaﾮ (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis. For more information o...
Investor releaseQuarter not tagged2026-03-04Cumberland Pharmaceuticals Q4 Earnings Call Highlights
MarketBeat
Cumberland Pharmaceuticals Q4 Earnings Call Highlights
Cumberland posted strong commercial results in 2025 with Q4 FDA-approved brand revenues of $13.7M (up 31% YoY) and full-year revenue of $44.5M (up 18%), narrowing net losses and improving operating cash flow to $4.9M and adjusted earnings to $1.7M ($0.11/share). Pipeline momentum was led by ifetroban, where phase II DMD data showed a 3.3% LVEF improvement versus placebo (5.4% vs matched natural-history controls); the program has Orphan, Rare Pediatric and Fast Track FDA designations and Cumberland is discussing next development steps with the agency. Management expanded the portfolio and international footprint—acquisitions and a Talicia JV added material assets, Vibativ secured approval in China and launched in Saudi Arabia (with a $3M milestone), and the company is targeting double-digit revenue growth and meaningful positive operating cash flow in 2026. Interested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better. Cumberland Pharmaceuticals (NASDAQ:CPIX) reported fourth-quarter and full-year 2025 results and provided a business update during its earnings call, highlighting revenue growth across its portfolio, progress in pipeline programs led by ifetroban, and continued expansion into international markets. Management said 2025 represented “an outstanding year,” citing commercial execution and expanded contributions from multiple brands. For the fourth quarter, Cumberland reported combined revenues from FDA-approved brands of $13.7 million, a 31% increase versus the prior-year period. Full-year 2025 revenues totaled $44.5 million, up 18% from 2024, meeting the company’s goal of double-digit revenue growth. → Defense Stocks Are Soaring—AeroVironment's Earnings Could Close the Gap Chief Financial Officer John Hamm said fourth-quarter net revenue from continuing operations was $13.7 million, up $3.2 million year over year. Net revenue by product in the fourth quarter was: Kristalose: $3.1 million Sancuso: $3.3 million Vibativ: $2.8 million Caldolor: $0.9 million Talicia: $3.3 million For the full year, Hamm reported product revenues of $10.5 million for Kristalose, $11.9 million for Sancuso, $9.4 million for Vibativ, $4.7 million for Caldolor, and $3.3 million for Talicia. Cumberland also received a $3 million milestone payment tied to Vibativ’s approval in China. → IonQ in Rebound Mode: Buy the Thesis, Respect the Risk Operating expens...
Investor releaseQuarter not tagged2026-03-04CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
PR Newswire
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
Cumberland to highlight 2025 financial, international, portfolio and clinical progress NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period. Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company's target of double digit revenue growth. Cumberland ended the year with $76.8 million in total assets, $52.3 million in liabilities and $24.9 million of shareholders' equity. The net loss for 2025 was $2.9 million, which was an improvement of $3.6 million from the prior year. When noncash items are added back the Adjusted Earnings for the full year were $1.7 million, a $2.7 million improvement over the prior year. In addition, cashflow from operations was $4.9 million in 2025 representing a $5.5 million increase over 2024. "We are pleased with Cumberland's strong financial performance in 2025, and the progress made across our commercial and development portfolio," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "We delivered solid revenue growth, expanded our international presence, strengthened our commercial platform with the addition of Talicia® and achieved important reimbursement and clinical milestones. These accomplishments reflect the strength of our strategy and position Cumberland for continued growth as we work together to provide unique products that improve the quality of patient care." 2025 HIGHLIGHTS INCLUDE: International Expansion In February 2025, Cumberland announced that its Vibativ® product received approval from the regulatory authorities in China, the world's second-largest pharmaceutical market. The announcement follows an agreement that provides SciClone Pharmaceuticals with the exclusive rights to register, promote and distribute the product to patients in the Chinese market. In September 2025, Cumberland announced the launch of Vibativ in Saudi Arabia. The product launch follows an agreement with Tabuk Pharmaceutical Manufacturing Company to introduce Vibativ into the Middle East. The arrangement provided Tabuk exclusive rights to distribute Vibativ in Saudi Arabia and Jordan, with the option to expand i...
Investor releaseQuarter not tagged2026-03-04Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ...
GuruFocus.com
Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ...
This article first appeared on GuruFocus. Release Date: March 03, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) achieved a 31% increase in fourth-quarter revenues, totaling $13.7 million, and an 18% increase in full-year revenues, reaching $44.5 million. The company strengthened its financial position by increasing shareholder equity and reducing its line of credit balance by over $10 million. CPIX expanded its global presence with regulatory approvals in China and Mexico, and successful product launches in Saudi Arabia. The company added Telicia, an FDA-approved treatment for Helicobacter pylori infections, to its portfolio, enhancing its presence in gastrointestinal care. CPIX's clinical pipeline showed significant progress, with breakthrough results from the F DMD clinical study and FDA fast track designation for its DMD program. CPIX faced increased operating expenses, rising from $12 million to $15 million in the fourth quarter, due to higher royalties and cost of goods. The company reported a net loss of $1.4 million for the fourth quarter and $2.9 million for the full year, despite improvements over the previous year. Crystallose faced increased substitution by pharmacies in favor of generic alternatives, impacting its sales. The company has ongoing financial commitments, including milestone payments and royalties tied to product sales, which could impact future cash flow. CPIX's total liabilities stood at $52.3 million, including $5.2 million on its credit facility, which could pose financial risks if not managed effectively. Warning! GuruFocus has detected 1 Warning Sign with CPIX. Is CPIX fairly valued? Test your thesis with our free DCF calculator. Q: Can you provide an overview of Cumberland Pharmaceuticals' financial performance for 2025? A: AJ Kazimi, CEO, reported that Cumberland Pharmaceuticals achieved a 31% increase in fourth-quarter revenues, totaling $13.7 million, and an 18% increase in full-year revenues, reaching $44.5 million. The company also improved adjusted earnings by over $2 million to $1.7 million or $0.11 per share, with cash flow from operations improving by $5.5 million. Q: What were the key drivers behind the revenue growth in 2025? A: AJ Kazimi, CEO, highlighted that the revenue growth was driven by strong demand for pr...
Investor releaseQuarter not tagged2026-03-04Cumberland (CPIX) Q4 2025 Earnings Call Transcript
Motley Fool
Cumberland (CPIX) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. Tuesday, March 3, 2026 at 4:30 p.m. ET Chief Executive Officer — A.J. Kazimi Vice President, Organizational Development — Todd Anthony Chief Financial Officer — John Hamm Need a quote from a Motley Fool analyst? Email [email protected] A.J. Kazimi, Cumberland Pharmaceuticals Inc.'s Chief Executive Officer; Todd Anthony, Vice President, Organizational Development; and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks, as well as uncertainties. There are many factors that could affect Cumberland Pharmaceuticals Inc.'s future results, including natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics, and others that are beyond the company's control. Those issues are described under the caption Risk Factors in Cumberland Pharmaceuticals Inc.'s Annual Report on Form 10-K and any subsequent updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations, so information shared on this call should be considered current as of today only. Also, please remember that the company is not responsible for updating any forward-looking statements whether as a result of new information or due to future developments. During today's call, there will be references to several of Cumberland Pharmaceuticals Inc.'s marketed brands. Full prescribing and safety information for each brand is included on the individual product website, and you can find links to those sites on the corporate site at www.cumberlandpharma.com. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to GAAP measures can be found in the tables of the earnings release that I noted was issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point we will be happy to answer them. Management is also prepared to hold a follow-up conversation with shareholders after the call if you prefer. With that introduction, I will turn the...